VRXA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
| Index | - | P/E | 9.38 | EPS (ttm) | 0.21 | Insider Own | 75.93% | Shs Outstand | 31.6M | Perf Week | -5.19% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 7.6M | Perf Month | -14.47% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | - | Inst Own | 46.18% | Short Float | 3.16% | Perf Quarter | -84.54% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.57 | Perf Half Y | -81.13% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | 2.52% | Short Interest | 0.24M | Perf YTD | -81.16% |
| Book/sh | -2.25 | P/C | 2118.69 | EPS past 3/5Y | - | ROE | 5.72% | 52W High | -92.65% ($27.36) | Perf Year | -80.65% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 18.24% ($1.70) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.24% | Gross Margin | - | Volatility(W/M) | 9.99% 16.25% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.92 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0 | EPS Q/Q | -91.03% | Profit Margin | - | RSI (14) | 37.02 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0 | Sales Q/Q | - | SMA20 | -6.5% ($2.15) | Beta | 0.25 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -71.64% ($7.09) | Rel Volume | 1.94 | Prev Close | $1.8 |
| Employees | 3 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -80% ($10.05) | Avg Volume(3M) | 0.42M | Price | $2.01 |
| IPO | 2024/9/30 | Option/Short | No/Yes | Trades | 2245 | Volume | 816,835 | Change | 11.67% |
Veraxa Biotech AG (VRXA) Investment Analysis
What kind of company is Veraxa Biotech AG?
🧬 A global clinical-stage biotech company developing next-generation antibody-based cancer therapeutics and antibody-drug conjugates (ADCs). Headquartered in Switzerland, it is building an innovative oncology pipeline based on a platform technology that selectively targets tumor sites to reduce side effects.
Learn more about Veraxa Biotech AG →Key Events
VRXA의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.
- 실적 발표는 보통 분기마다 있습니다
- 배당주는 연 1~4회 배당락일이 있습니다
Is it profitable?
What's the outlook?
Analyst estimates and price targets have not been collected.
Did earnings meet expectations?
No analyzable past earnings releases have been collected yet.
Has the stock risen over the long term?
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current price $2.01 below the midline ($2.15). Normal downward flow. Below the Ichimoku cloud (bearish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
MACD -1.430 · Signal -1.759 · Hist 0.329. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
RSI 37.0 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 13.5.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Who owns it?
How much does it pay in dividends?
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| VRXA This Stock | $63.6M | 9.4 ▲ | - | 5.72% ▲ | - | +11.7% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is VRXA?
VRXA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRXA?
The market cap of VRXA is approximately $64M, ranking 4,815 within its sector.
What is the P/E ratio of VRXA?
VRXA has a P/E ratio of approximately 9.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VRXA?
VRXA has recorded a 52-week high of $27.36 and a low of $1.70.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.